• Koichi IsobeEmail author


The gastric lymphomas include several histological subtypes of lymphoma, including diffuse large B-cell lymphoma (DLBCL), marginal zone B-cell lymphoma of mucosa associated lymphoid tissue (MALT lymphoma), follicular lymphoma, mantle cell lymphoma, adult T-cell lymphoma/leukemia, and so on. Of these, DLBCL and MALT lymphoma account for approximately 90% of gastric lymphomas. For localized DLBCL, the 30 Gy of conventionally fractionated radiation therapy (RT) following the short course of anthracycline-based chemotherapy combined with rituximab, such as R-CHOP regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) is a treatment of choice. On the contrary, the antibiotics for Helicobacter pylori (H. pylori) are first line treatment for H. pylori-positive MALT lymphoma. The H. pylori-negative cases and those who fail H. pylori eradication therapy are candidates for RT. Irrespective of histological subtypes, clinical target volume is defined as whole gastric wall. During simulation and delivery of RT, the management of inter- and intrafractional gastric motion is indispensable for gastric lymphomas. RT with doses up to 30 Gy could produce excellent local control and long-term outcomes without significant late effects in MALT lymphoma.


Gastric lymphoma Interfractional motion Intrafractional motion Radiation therapy 


  1. 1.
    Neubauer A, Zucca E. Gastrointestinal tract lymphomas. In: Cavalli F, Stein H, Zucca E, editors. Extranodal lymphomas. UK: Informa; 2008. p. 233–43.CrossRefGoogle Scholar
  2. 2.
    Zucca E, Cavalli F. Extranodal lymphomas. Ann Oncol. 2000;11(Suppl 3):219–22.CrossRefPubMedGoogle Scholar
  3. 3.
    Zucca E, Roggero E, Bertoni F, Cavalli F. Primary extranodal non-Hodgkin’s lymphomas. Part 1: Gastrointestinal, cutaneous, and genitourinary lymphomas. Ann Oncol. 1997;8:727–37.CrossRefPubMedGoogle Scholar
  4. 4.
    Chimire P, GY W, Zhu L. Primary gastrointestinal lymphoma. World J Gastroenterol. 2011;17:697–707.CrossRefGoogle Scholar
  5. 5.
    Nakamura S, Matsumoto T, Iida M, Yao T, Tsuneyoshi M. Primary gastrointestinal lymphoma in Japan: a clinicopathologic analysis of 455 patients with special reference to its time trends. Cancer. 2003;97:2462–73.CrossRefPubMedGoogle Scholar
  6. 6.
    Papaxoinis G, Papageorgiou S, Rontogianni D, Kaloutsi V, Fountzilas G, Pavlidis N, et al. Primary gastrointestinal non-Hodgkin’s lymphoma: a clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG). Leuk Lymphoma. 2006;47:2040–6.CrossRefGoogle Scholar
  7. 7.
    Koch P, Probst A, Berdel WE, Willich NA, Reinartz G, Brockmann J, et al. Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96). J Clin Oncol. 2005;23:7050–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Ferreri AJ, Montalban C. Primary diffuse large B-cell lymphoma of the stomach. Crit Rev Oncol Hematol. 2007;63:65–71.CrossRefPubMedGoogle Scholar
  9. 9.
    Hussell T, Isaacson PG, Crabtree JE, Spencer J. The response of cells from low grad B-cell gastric lymphomas of mucosa associated lymphoid tissue to Helicobacter pylori. Lancet. 1993;342:571–4.CrossRefPubMedGoogle Scholar
  10. 10.
    Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edition. Lyon, France: IARC Press; 2008.Google Scholar
  11. 11.
    Dreyling M, Thieblemont C, Gallamini A, Arcaini L, Campo E, Hermine O, et al. ESMO consensus conferences: guidelines on malignant lymphoma. Part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol. 2013;24:857–77.CrossRefPubMedGoogle Scholar
  12. 12.
    Ruskone-Fourmestraux A, Fishbach W, Aleman BM, Boot H, Du MQ, Megraud F, et al. EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut. 2011;60:747–58.CrossRefPubMedGoogle Scholar
  13. 13.
    Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–67.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Zucca E, Copie-Bergman C, Ricardi U, Thieblemont C, Raderer M, Ladetto M, et al. Gastric marginal zone lymphoma of MALT type: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:144–8.CrossRefGoogle Scholar
  15. 15.
    Zollo A, Hassan C, Ridola L, Repici A, Manta R, Andriani A. Gastric MALT lymphoma. Old and new insights. Ann Gastroenterol. 2014;27:27–33.Google Scholar
  16. 16.
    Vetro C, Romano A, Amico I, Conticello C, Motta G, Figuera A, et al. Endoscopic features of gastro-intestinal lymphomas: From diagnosis to follow up. World J Gastroenterol. 2014;20:12993–3005.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Fusaroli P, Caletti G. Endoscopic ultrasonography: current clinical role. Eur J Gastroenterol Hepatol. 2005;17:293–301.CrossRefPubMedGoogle Scholar
  18. 18.
    Isomoto H, Shikuwa S, Yamaguchi N, Miyazato K, Ohnita K, Hayashi T, et al. Magnified endoscopic findings of gastric low grade mucosa associated lymphoid tissue lymphoma. Endoscopy. 2008;40:225–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Rohatiner A, d’Amore F, Coiffier B, Crowther D, Gospodarowicz M, Isaacson P, et al. Report on a workshop convened to discuss the pathological and staging classification of gastrointestinal tract lymphoma. Ann Oncol. 1994;5:397–400.CrossRefPubMedGoogle Scholar
  20. 20.
    Ruskone-Fourmestraux A, Dragosics B, Morgner A, Wotherspoon A, De Jong D. Paris staging system for primary gastrointestinal lymphomas. Gut. 2003;52:912–3.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Musshoff K. Clinical staging classification of non-Hodgkin’s lymphoma. Strahlentherapie. 1977;153:218–21.PubMedGoogle Scholar
  22. 22.
    Janssen J. The impact of EUS in primary gastric lymphoma. Best Pract Res Clin Gastroenterol. 2009;23:671–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258–65.CrossRefPubMedGoogle Scholar
  24. 24.
    A predictive model for aggressive non-Hodgkin’s lymphoma. The international Non-Hodgkin’s lymphoma prognostic factors project. N Engl J Med. 1993;329:987–94.Google Scholar
  25. 25.
    Thirlby RC. Gastrointestinal lymphoma: a surgical perspective. Oncology. 1993;7:29–32.PubMedGoogle Scholar
  26. 26.
    Sano T. Treatment of primary gastric lymphoma: experience in the National Cancer Center Hospital, Tokyo. Recent Results Cancer Res. 2000;156:104–7.CrossRefPubMedGoogle Scholar
  27. 27.
    d’Amore F, Brincker H, Gronbaek K, Thorling K, Pedersen M, Jensen MK, et al. Non-Hodgkin’s lymphoma of the gastrointestinal tract: a population-based analysis of incidence, geographic distribution, clinicopathologic presentation features, and prognosis. J Clin Oncol. 1994;12:1673–84.CrossRefPubMedGoogle Scholar
  28. 28.
    Binn M, Ruskone-Fourmestraux A, Lepage E, Haioun C, Delmer A, Aegerter P, et al. Surgical resection plus chemotherapy versus chemotherapy alone: comparison of two strategies to treat diffuse large B-cell gastric lymphoma. Ann Oncol. 2003;14:1751–7.CrossRefPubMedGoogle Scholar
  29. 29.
    Ishikura S, Tobinai K, Ohtsu A, Nakamura S, Yoshino T, Oda I, et al. Japanese multicenter phase II study of CHOP followed by radiotherapy in stage I–II, diffuse large B-cell lymphoma of the stomach. Cancer Sci. 2005;96:349–52.CrossRefPubMedGoogle Scholar
  30. 30.
    Yoon SS, Coit DG, Portlock CS, Karpeh MS. The diminishing role of surgery in the treatment of gastric lymphoma. Ann Surg. 2004;240:28–37.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Martinelli G, Gigli F, Calabrese L, Ferrucci PF, Zucca E, Crosta C, et al. Early stage gastric diffuse large B-cell lymphomas: results of a randomized trial comparing chemotherapy alone versus chemotherapy + involved field radiotherapy (IELSG 4) [corrected]. Leuk Lymphoma. 2009;50:925–31.CrossRefPubMedGoogle Scholar
  32. 32.
    Zullo A, Hassan C, Ridola L, De Francesco V, Rossi L, Tomao S, et al. Eradication therapy in helicobacter pylori negative gastric low grade mucosa associated lymphoid tissue (MALT) lymphoma patients. A systematic review. J Clin Gastroenterol. 2013;47:824–7.CrossRefPubMedGoogle Scholar
  33. 33.
    Tsang RW, Gospodarowicz MK, Pintilie M, Wells W, Hodgson DC, Sun A, et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol. 2003;21:4157–64.CrossRefPubMedGoogle Scholar
  34. 34.
    Wirth A, Gospodarowicz MK, Aleman BM, Bressel M, Ng A, Chao M, et al. Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-centre, International Extranodal Lymphoma Study Group study. Ann Oncol. 2013;24:1344–51.CrossRefPubMedGoogle Scholar
  35. 35.
    Ruskone-Fourmestraux A, Matysiak-Budnik T, Fabiani B, Cervera P, Brixi H, Le Malicot K, et al. Exclusive moderate-dose radiotherapy in gastric marginal zone B-cell MALT lymphoma: results of a prospective stud with a long term follow up. Radiother Oncol. 2015;117:178–82.CrossRefPubMedGoogle Scholar
  36. 36.
    Isobe K, Uno T, Kawakami H, Ueno N, Kawata T, Ito H. A case of gastric lymphoma with marked interfractional gastric movement during radiation therapy. Int J Clin Oncol. 2006;11:159–61.CrossRefPubMedGoogle Scholar
  37. 37.
    Watanabe M, Isobe K, Takishima H, Uno T, Ueno N, Kawakami H, et al. Intrafractional gastric and interfractional stomach deformity during radiation therapy. Radiother Oncol. 2008;87:425–31.CrossRefPubMedGoogle Scholar
  38. 38.
    Watanabe M, Isobe K, Uno T, Harada R, Kobayashi H, Ueno N, et al. Intrafractional gastric motion and interfractional stoma deformity using CT images. J Radiat Res. 2011;52(5):660.CrossRefPubMedGoogle Scholar
  39. 39.
    Tsang RW, Gospodarowicz MK. Low-grade non-Hodgkin’s lymphomas. Semin Radiat Oncol. 2007;17:198–205.CrossRefPubMedGoogle Scholar
  40. 40.
    Yahalom J, Illidge T, Specht L, Hoppe RT, Li YX, Tsang R, et al. Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the international lymphoma radiation oncology group. Int J Radiat Oncol Biol Phys. 2015;92:11–31.CrossRefPubMedGoogle Scholar
  41. 41.
    Psyrri A, Papageorgiou S, Economopoulos T. Primary extranodal lymphoma of stomach: clinical presentation, diagnostic pitfalls and management. Ann Oncol. 2008;19:1992–9.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Prosnitz LR, Palta M, Kelsey CR. Non-Hodgkin lymphomas. In: Halperin EC, Wazer DE, Perez CA, Brady LW, editors. Principles and practice of radiation oncology. Philadelphia: Lippincott Williams & Wilkins; 2013. p. 1547–73.Google Scholar
  43. 43.
    Abe S, Oda I, Inaba K, Suzuki H, Yoshinaga S, Nonaka S, et al. A retrospective study of 5-year outcomes of radiotherapy for gastric mucosa-associated lymphoid tissue lymphoma refractory to Helicobacter pylori eradication therapy. Jpn J Clin Oncol. 2013;43:917–22.CrossRefPubMedGoogle Scholar
  44. 44.
    Kal HB, van Kempen-Harteveld ML. Renal dysfunction after total body irradiation: dose-effect relationship. Int J Radiat Oncol Biol Phys. 2006;65:1228–32.CrossRefPubMedGoogle Scholar
  45. 45.
    Esiashvili N, Chiang KY, Hasselle MD, Bryant C, Riffenburgh RH, Paulino AC. Renal toxicity in children undergoing total body irradiation for bone marrow transplant. Radiother Oncol. 2009;90:242–6.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Japan 2017

Authors and Affiliations

  1. 1.Department of RadiologyToho University Sakura Medical CenterSakuraJapan

Personalised recommendations